CSL und Alentis geben weltweite Partnerschaft zur Entwicklung und Vermarktung von lixudebart für seltene Nieren- und Lebererkrankungen bekannt

Summary

CSL and Alentis Therapeutics announced a global partnership for the development and commercialization of lixudebart for rare kidney and liver diseases, with Alentis receiving $355 million upfront and up to $1.2 billion in commercial milestone payments, with worldwide profits to be shared.